CTLA4 and lung carcinoma: In this regard, the advent of immune checkpoint inhibitors (ICIs) targeting either CTLA-4, PD-1, or PD-L1 has revolutionized the field of cancer therapy, resulting in sustained clinical remissions in patients otherwise refractory to standard of cancer therapies in many cancer types, including melanomas and lung cancers.